Does the size of pelvic lymph nodes predict metastatic involvement in patients with endometrial cancer?

1996 ◽  
Vol 6 (6) ◽  
pp. 445-447 ◽  
Author(s):  
O. Reich ◽  
R. Winter ◽  
H. Pickel ◽  
K. Tamussino ◽  
J. Haas ◽  
...  
2020 ◽  
Author(s):  
Aljosa Mandic ◽  
Dunja Kokanov ◽  
Bojana Gutic ◽  
Tatjana Ivkovic Kapicl ◽  
Slobodan Maricic ◽  
...  

2009 ◽  
Vol 115 (1) ◽  
pp. 12-17 ◽  
Author(s):  
Gunda Pristauz ◽  
Arnim A. Bader ◽  
Peter Regitnig ◽  
Josef Haas ◽  
Raimund Winter ◽  
...  

2019 ◽  
Vol 154 (1) ◽  
pp. 60-64 ◽  
Author(s):  
Francesco Multinu ◽  
Jvan Casarin ◽  
Serena Cappuccio ◽  
Gary L. Keeney ◽  
Gretchen E. Glaser ◽  
...  

2017 ◽  
Vol 145 ◽  
pp. 110
Author(s):  
V. Zanfagnin ◽  
J. Casarin ◽  
F. Multinu ◽  
K.J. Schoolmeester ◽  
Y. Huang ◽  
...  

2021 ◽  
pp. ijgc-2021-002924
Author(s):  
Sarah E Gill ◽  
Simone Garzon ◽  
Francesco Multinu ◽  
Alexis N Hokenstad ◽  
Jvan Casarin ◽  
...  

ObjectiveEvidence on micrometastases and isolated tumor cells as factors associated with non-vaginal recurrence in low- and intermediate-risk endometrial cancer is limited. The goal of our study was to investigate risk factors for non-vaginal recurrence in low- and intermediate-risk endometrial cancer.MethodsRecords of all patients with endometrial cancer surgically managed at the Mayo Clinic before sentinel lymph node implementation (1999–2008) were reviewed. We identified all patients with endometrioid low-risk (International Federation of Gynecology and Obstetrics (FIGO) stage I, grade 1 or 2 with myometrial invasion <50% and negative peritoneal cytology) or intermediate-risk (FIGO stage I, grade 1 or 2 with myometrial invasion ≥50% or grade 3 with myometrial invasion <50% and negative peritoneal cytology) endometrial cancer at definitive pathology after pelvic and para-aortic lymph node assessment. All pelvic lymph nodes of patients with non-vaginal recurrence (any recurrence excluding isolated vaginal cuff recurrences) underwent ultrastaging.ResultsAmong 1303 women, we identified 321 patients with low-risk (n=236) or intermediate-risk (n=85) endometrial cancer (median age 65.4 years; 266 (82.9%) stage IA; 55 (17.1%) stage IB). Of the total of 321, 13 patients developed non-vaginal recurrence (Kaplan–Meier rate 4.7% by 60 months; 95% CI 2.1% to 7.2%): 11 hematogenous/peritoneal and two para-aortic and distant lymphatic. Myometrial invasion and lymphovascular space invasion were univariately associated with non-vaginal recurrence. In these patients, the original hematoxylin/eosin slides review confirmed all 646 pelvic and para-aortic removed lymph nodes as negative. The ultrastaging of 463 pelvic lymph nodes did not identify any occult metastases (prevalence 0%; 95% CI 0% to 22.8% considering 13 patients; 95% CI 0% to 0.8% considering 463 pelvic lymph nodes).ConclusionThere were no occult metastases in pelvic lymph nodes of patients with low- or intermediate-risk endometrial cancer with non-vaginal recurrence. Myometrial invasion and lymphovascular space invasion appear to be associated with non-vaginal recurrence.


Sign in / Sign up

Export Citation Format

Share Document